Innovative Low-Cost Drug Formulation Enhances Treatment for Parasitic Worms

A team of researchers has developed an innovative, affordable formulation of the primary drug used to combat helminth infections, such as schistosomes and tapeworms. According to the World Health Organization, over 400 million individuals worldwide suffer from these parasitic infections. The commonly used medication, praziquantel, is traditionally supplied in large, bitter-tasting tablets that are often difficult to swallow, especially for children and pets, complicating treatment efforts.

The new formulation, based on nanotechnology, significantly improves the drug's water solubility and absorption. Remarkably, it requires only half the standard dose to produce the same therapeutic effect, which could lead to lower treatment costs and increased accessibility. A patent application has been filed for this advanced formulation, and its efficacy has been validated through published research in ACS Applied Nano Materials.

Developed at the Research Center for Neglected Diseases at Guarulhos University in São Paulo, Brazil, the formulation takes advantage of a two-phase system: one oil-based phase utilizing castor oil to enhance absorption through human cell membranes, and another phase that emulsifies in the stomach. This design prolongs the drug's presence in blood plasma, facilitating effective treatment with reduced dosage. Laboratory tests have shown low toxicity and greater effectiveness in eliminating schistosomes compared to the active ingredient alone.

This innovation aligns with global efforts to control neglected tropical diseases, particularly in vulnerable populations lacking access to new treatments. The formulation's stability at room temperature, potential for combination with other active ingredients, and suitability for pharmaceutical and veterinary markets make it a promising development. Its ease of production and storage could accelerate large-scale manufacturing and distribution.

While further clinical trials are necessary before human use, the formulation's compatibility with veterinary applications could improve parasite control in pets, which also pose zoonotic risks to humans. The researchers are seeking partnerships to advance clinical testing and commercialize this low-cost, effective solution, contributing to the global campaign against parasitic diseases.